Azacitidine

CHEMBL1489 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

244.2 g/mol

LogP

-2.2

Phase

4

A hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, reactivating silenced tumor suppressor genes in abnormal blood cells. It is used in myelodysplastic syndromes and acute myeloid leukemia to slow disease progression.

Molecular Weight

244.2000 g/mol

LogP

-2.20

TPSA

141.00 Å²

Lipinski RO5

Pass

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Anesthesiology Asthma Atopic Dermatitis Atrial Fibrillation Benign Prostatic Hyperplasia Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Deep Vein Thrombosis / Pulmonary Embolism Dermatology Endocrinology Endometriosis Epilepsy Gastroenterology Gastroesophageal Reflux Disease Generalized Anxiety Disorder Glaucoma Gout Heart Failure Hematology Hepatitis C Hepatology HIV/AIDS Hyperlipidemia Hypertension Immunology Infectious Disease Inflammatory Bowel Disease Insomnia Leukemia Lymphoma Major Depressive Disorder Malaria Melanoma Migraine Multiple Sclerosis Nephrology Neurology Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Obstetrics & Gynecology Oncology Ophthalmology Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Psoriasis Psychiatry Respiratory Disease Rheumatoid Arthritis Rheumatology Schizophrenia Stroke Systemic Lupus Erythematosus Thyroid Cancer Transplant Medicine Tuberculosis Type 2 Diabetes Urology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1

InChI

InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1

Molecular Formula

C8H12N4O5

HBD / HBA

4 / 5

Rotatable Bonds

2

Heavy Atoms

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, reactivating silenced tumor suppressor genes in abnormal blood cells. It is used in myelodysplastic syndromes and acute myeloid leukemia to slow disease progression.

Yes, Azacitidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1489. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Azacitidine on PillFYI

Structure

Quick Data

Formula: C8H12N4O5
Synonyms: 3

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.